Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon Aug 19, 2021 11:20am
131 Views
Post# 33730346

RE:RE:Way Forward

RE:RE:Way ForwardUnfortunately I don't think Q2 financials will prompt our analyst to change his forecast.  I believe that James also stated back in April that Aristotle was in action as he spoke.  Actual revenue improvement following the CARE deal will be the new catalyst and we will have to await a couple of quarters to find out - analyst predictions could change then.  In the interim, I doubt that rhetoric will move the needle. 


davewho wrote: our new Director does say at the 30 min mark that they intend to cover as many patients as possible in the shortest period of time. James also said that they are ready to start booking the new rev now. I guess we will find out shortly if they are truely organised or not. I'm also still waiting to see if our analyst chimes in over the next few days.


<< Previous
Bullboard Posts
Next >>